Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15243006rdf:typepubmed:Citationlld:pubmed
pubmed-article:15243006lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:15243006lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:15243006lifeskim:mentionsumls-concept:C0015915lld:lifeskim
pubmed-article:15243006lifeskim:mentionsumls-concept:C0025186lld:lifeskim
pubmed-article:15243006lifeskim:mentionsumls-concept:C0008625lld:lifeskim
pubmed-article:15243006lifeskim:mentionsumls-concept:C0038323lld:lifeskim
pubmed-article:15243006lifeskim:mentionsumls-concept:C1441547lld:lifeskim
pubmed-article:15243006lifeskim:mentionsumls-concept:C1521828lld:lifeskim
pubmed-article:15243006lifeskim:mentionsumls-concept:C1511572lld:lifeskim
pubmed-article:15243006lifeskim:mentionsumls-concept:C0150312lld:lifeskim
pubmed-article:15243006lifeskim:mentionsumls-concept:C0390817lld:lifeskim
pubmed-article:15243006pubmed:issue9lld:pubmed
pubmed-article:15243006pubmed:dateCreated2004-8-23lld:pubmed
pubmed-article:15243006pubmed:abstractTextThe objective of the study was to investigate the effect of Follicular-Fluid Meiosis Activating Sterol (FF-MAS) when added to the culture media on the incidence of chromosomal abnormalities and pre-embryo development in human pre-embryos.lld:pubmed
pubmed-article:15243006pubmed:languageenglld:pubmed
pubmed-article:15243006pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15243006pubmed:citationSubsetIMlld:pubmed
pubmed-article:15243006pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15243006pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15243006pubmed:statusMEDLINElld:pubmed
pubmed-article:15243006pubmed:monthSeplld:pubmed
pubmed-article:15243006pubmed:issn0268-1161lld:pubmed
pubmed-article:15243006pubmed:authorpubmed-author:WiklandMattsMlld:pubmed
pubmed-article:15243006pubmed:authorpubmed-author:LundinKerstiKlld:pubmed
pubmed-article:15243006pubmed:authorpubmed-author:BerghChristin...lld:pubmed
pubmed-article:15243006pubmed:authorpubmed-author:LoftAnneAlld:pubmed
pubmed-article:15243006pubmed:authorpubmed-author:NilssonLarsLlld:pubmed
pubmed-article:15243006pubmed:authorpubmed-author:ArceJ-CJClld:pubmed
pubmed-article:15243006pubmed:authorpubmed-author:ZiebeSörenSlld:pubmed
pubmed-article:15243006pubmed:authorpubmed-author:GröndahlChris...lld:pubmed
pubmed-article:15243006pubmed:authorpubmed-author:CEMAS II...lld:pubmed
pubmed-article:15243006pubmed:issnTypePrintlld:pubmed
pubmed-article:15243006pubmed:volume19lld:pubmed
pubmed-article:15243006pubmed:ownerNLMlld:pubmed
pubmed-article:15243006pubmed:authorsCompleteYlld:pubmed
pubmed-article:15243006pubmed:pagination2109-17lld:pubmed
pubmed-article:15243006pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:meshHeadingpubmed-meshheading:15243006...lld:pubmed
pubmed-article:15243006pubmed:year2004lld:pubmed
pubmed-article:15243006pubmed:articleTitleChromosomal abnormality rate in human pre-embryos derived from in vitro fertilization cycles cultured in the presence of Follicular-Fluid Meiosis Activating Sterol (FF-MAS).lld:pubmed
pubmed-article:15243006pubmed:affiliationReproductive Medicine, Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Göteborg, Sweden. christina.bergh@vgregion.selld:pubmed
pubmed-article:15243006pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15243006pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15243006pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:15243006pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:15243006pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:15243006pubmed:publicationTypeClinical Trial, Phase Illd:pubmed